AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34013498 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of herpes zoster (HZ) patients
Number of subjects: 545
Study 34013498 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients
Number of subjects: 545
Study 34013969 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 48509
Study 34014326 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated screening at any visit
Number of subjects: 93114
Study 34014326 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered screening approach
Number of subjects: 93114
Study 34014326 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust practice facilitation and EHR usability testing
Number of subjects: 93114
Study 34014326 — intervention group
Group type: COMPARATOR
Intervention: Annual examinations only
Number of subjects: 93114
Study 34014326 — intervention group
Group type: COMPARATOR
Intervention: Staff-administered screening approach
Number of subjects: 93114
Study 34014326 — intervention group
Group type: EXPERIMENTAL
Intervention: All clinics
Number of subjects: 93114
Study 34014429 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Intervention (GI)
Number of subjects: 0
Study 34014429 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Counselling (IC)
Number of subjects: 0
Study 34014429 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective Advocacy (CA)
Number of subjects: 0
Study 34014429 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 0
Study 34014549 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 222
Study 34014839 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS)
Number of subjects: 12353
Study 34014839 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS of oxidative hemolysis
Number of subjects: 12353
Study 34014839 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of genome-wide significant loci
Number of subjects: 12353
Study 34015091 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution peripheral quantitative CT (HR-pQCT) of two metacarpophalangeal (MCP) joints
Number of subjects: 353
Study 34015091 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography (CR) of 44 joints
Number of subjects: 353
Study 34015096 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically closed ASD
Number of subjects: 53
Study 34015096 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneously closed ASD
Number of subjects: 53
Study 34015096 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 53
Study 34015112 — intervention group
Group type: EXPERIMENTAL
Intervention: SPUM-ACS Score
Number of subjects: 2168
Study 34015112 — intervention group
Group type: COMPARATOR
Intervention: GRACE 2.0 Score
Number of subjects: 2168
Study 34015141 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive and behavioural therapy (I-C/BT) with therapist guidance
Number of subjects: 808
Study 34015141 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive and behavioural therapy (I-C/BT)
Number of subjects: 808
Study 34015791 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Electrically Administered Seizure Therapy (FEAST)
Number of subjects: 39
Study 34015791 — intervention group
Group type: COMPARATOR
Intervention: Ultrabrief Pulse Right Unilateral Electroconvulsive Therapy (UB-RUL ECT)
Number of subjects: 39
Study 34016140 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals consumed at home
Number of subjects: 0
Study 34016140 — intervention group
Group type: COMPARATOR
Intervention: Meals consumed away from home
Number of subjects: 0
Study 34016140 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals eaten with company
Number of subjects: 0
Study 34016140 — intervention group
Group type: COMPARATOR
Intervention: Meals eaten without company
Number of subjects: 0
Study 34016140 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with screen time
Number of subjects: 0
Study 34016140 — intervention group
Group type: COMPARATOR
Intervention: Meals without screen time
Number of subjects: 0
Study 34016182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 7
Study 34016423 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Number of subjects: 0
Study 34016423 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous revascularization
Number of subjects: 0
Study 34016423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid revascularization
Number of subjects: 0
Study 34016423 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34016561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (MN-166), dosage and duration not specified
Number of subjects: 0
Study 34016656 — intervention group
Group type: EXPERIMENTAL
Intervention: United States cohort
Number of subjects: 0
Study 34016656 — intervention group
Group type: COMPARATOR
Intervention: Canadian cohort
Number of subjects: 0
Study 34016873 — intervention group
Group type: EXPERIMENTAL
Intervention: High pancreatic enzyme replacement therapy (PERT) dosing (>2000 lipase units/kg per meal)
Number of subjects: 231
Study 34016873 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of acid suppressive medications
Number of subjects: 231
Study 34016873 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of fecal calprotectin (fCP) (>200 μg/g)
Number of subjects: 231
Study 34016873 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundance of fecal Klebsiella pneumoniae
Number of subjects: 231
Study 34016873 — intervention group
Group type: EXPERIMENTAL
Intervention: GI-related hospitalization
Number of subjects: 231
Study 34016877 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Obesity (MO)
Number of subjects: 221
Study 34016877 — intervention group
Group type: COMPARATOR
Intervention: Normal-Weight Mothers (NWM)
Number of subjects: 221
Study 34016879 — intervention group
Group type: EXPERIMENTAL
Intervention: BSEP deficiency (n=53, including 8 with biallelic truncating mutations and 10 with mild mutations)
Number of subjects: 98
Study 34016879 — intervention group
Group type: EXPERIMENTAL
Intervention: FIC1 deficiency (n=26)
Number of subjects: 98
Study 34016879 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR3 deficiency (n=19, including four monoallelic)
Number of subjects: 98
Study 34016879 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical interruption of enterohepatic circulation (sEHC)
Number of subjects: 98
Study 34016879 — intervention group
Group type: EXPERIMENTAL
Intervention: liver transplant (LT) after sEHC
Number of subjects: 98
Study 34017073 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ruxolitinib b.i.d. for the first 12 weeks, then up-titrations of up to 25 mg b.i.d. based on efficacy and platelet counts
Number of subjects: 51
Study 34017263 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine treatment
Number of subjects: 0
Study 34017270 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34017617 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg press and hip abduction maximal strength training (MST) 3 times per week for 8 weeks, using heavy loads (85-90% of 1 repetition maximum; 1RM) and 4-5 repetitions in 4 sets.
Number of subjects: 21
Study 34017617 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (CG) for 8 weeks.
Number of subjects: 21
Study 34017848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hyperinflation
Number of subjects: 0
Study 34017848 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 34017869 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld ECG tracking
Number of subjects: 0
Study 34017869 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard monitoring)
Number of subjects: 0
Study 34018141 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP on postoperative day 5
Number of subjects: 95
Study 34018141 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP results ≥ 15.3 mg/dL on day 3
Number of subjects: 95
Study 34018141 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP results ≥ 9.1 mg/dL on day 5
Number of subjects: 95
Study 34018141 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal CRP and PCT values
Number of subjects: 95
Study 34018141 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP and PCT on days 3 and 5
Number of subjects: 95
Study 34019108 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily from Days 9-18
Number of subjects: 0
Study 34019108 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily from Days 9-18
Number of subjects: 0
Study 34019108 — intervention group
Group type: COMPARATOR
Intervention: Fedratinib 500 mg on Day 1 and Day 17
Number of subjects: 0
Study 34019229 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing risankizumab treatment
Number of subjects: 336
Study 34019229 — intervention group
Group type: COMPARATOR
Intervention: Withdrawing from risankizumab treatment
Number of subjects: 336
Study 34019439 — intervention group
Group type: EXPERIMENTAL
Intervention: Beach Chair Position (BC)
Number of subjects: 714
Study 34019439 — intervention group
Group type: COMPARATOR
Intervention: Lateral Decubitus Position (LD)
Number of subjects: 714
Study 34019468 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23 (8 weeks later)
Number of subjects: 0
Study 34019468 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23 (26 weeks later)
Number of subjects: 0
Study 34019468 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 (8 weeks after PCV13)
Number of subjects: 0
Study 34019468 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 (26 weeks after PCV13)
Number of subjects: 0
Study 34019468 — intervention group
Group type: EXPERIMENTAL
Intervention: PPSV23 (8 weeks or 26 weeks after PCV13)
Number of subjects: 0
Study 34019698 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) as perioperative treatment.
Number of subjects: 0
Study 34019698 — intervention group
Group type: COMPARATOR
Intervention: FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) alone as perioperative treatment.
Number of subjects: 0
Study 34020114 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34020147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative electrocorticography (ECoG) guided extended lesionectomy
Number of subjects: 85
Study 34020147 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual epileptic waves detected by intraoperative ECoG
Number of subjects: 85
Study 34020147 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant focal cortical dysplasia (FCD)
Number of subjects: 85
Study 34020147 — intervention group
Group type: COMPARATOR
Intervention: Patients with CRE without FCD
Number of subjects: 85
Study 34020272 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 0
Study 34020607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RNA + DNA extraction method
Number of subjects: 0
Study 34020607 — intervention group
Group type: EXPERIMENTAL
Intervention: emm75 qPCR
Number of subjects: 0
Study 34020607 — intervention group
Group type: COMPARATOR
Intervention: Traditional separate RNA-only and DNA-only extractions
Number of subjects: 0
Study 34020637 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography-based predictive model for FEV1
Number of subjects: 160
Study 34020637 — intervention group
Group type: COMPARATOR
Intervention: Spirometry (gold standard)
Number of subjects: 160
Study 34020658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 19960
Study 34020900 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital atherectomy (OA) via transradial access (TRA) followed by balloon angioplasty
Number of subjects: 50
Study 34021063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low weight-for-height (WHZ) only
Number of subjects: 0
Study 34021063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WHZ
Number of subjects: 0
Study 34021573 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption (1-7 cups/week)
Number of subjects: 25462
Study 34021573 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption (>1 cup/day)
Number of subjects: 25462
Study 34021573 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption (1-7 cups/week) in meta-analysis of both cohorts
Number of subjects: 25462
Study 34021573 — intervention group
Group type: COMPARATOR
Intervention: Caffeinated coffee consumption (≤3 cups/month)
Number of subjects: 25462
Study 34021827 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid antigen tests (RATs) for SARS-CoV-2; tested three times per week for two weeks.
Number of subjects: 36
Study 34021827 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcription polymerase chain reaction (RT-PCR); tested concurrently with RATs.
Number of subjects: 36
Study 34021886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel for pALL
Number of subjects: 0
Study 34021886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel for DLBCL
Number of subjects: 0
Study 34021886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 0
Study 34022160 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34022380 — intervention group
Group type: EXPERIMENTAL
Intervention: CTAG device
Number of subjects: 66
Study 34022621 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray
Number of subjects: 175
Study 34022698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-checkpoint inhibitors (ICI)
Number of subjects: 1485
Study 34022698 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1485
Study 34022795 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH-CBT guided by lay providers (LPs)
Number of subjects: 90
Study 34022795 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 90
Study 34022795 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH-CBT guided by LPs
Number of subjects: 90
Study 34022802 — intervention group
Group type: EXPERIMENTAL
Intervention: High somatization (HS) group
Number of subjects: 47
Study 34022802 — intervention group
Group type: COMPARATOR
Intervention: Low somatization (LS) group
Number of subjects: 47
Study 34022805 — intervention group
Group type: EXPERIMENTAL
Intervention: HATMD (present)
Number of subjects: 185
Study 34022813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Number of subjects: 94
Study 34022820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly HIV prevention services including clinical examination, HIV testing, screening and treatment for other sexually transmitted infections, peer-led counselling and support, provision of condoms and lubricants.
Number of subjects: 618
Study 34022820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly HIV prevention services
Number of subjects: 618
Study 34022820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly follow-up visits
Number of subjects: 618
Study 34022826 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA:D® Back programme (10-week programme consisting of 2 educational and 16 supervised exercise sessions)
Number of subjects: 1730
Study 34022826 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA:D® Back programme
Number of subjects: 1730
Study 34022955 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP-MS intervention (tailored blended physiotherapy intervention with online platform)
Number of subjects: 21
Study 34022988 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care interventions (including respiratory support such as high flow oxygenation, continuous positive airway pressure, invasive mechanical ventilation)
Number of subjects: 3140
Study 34022988 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 3140
Study 34022988 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 3140
Study 34023224 — intervention group
Group type: EXPERIMENTAL
Intervention: NIA-AA criteria with comprehensive neuropsychological evaluation
Number of subjects: 431
Study 34023224 — intervention group
Group type: COMPARATOR
Intervention: DSM-5 criteria with cognitive screener
Number of subjects: 431
Study 34023254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Magnetic Resonance at 0.55-T
Number of subjects: 0
Study 34023254 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular Magnetic Resonance at 1.5-T
Number of subjects: 0
Study 34023255 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststent OCT findings with significant malapposition (TMV ≥7.0 mm)
Number of subjects: 1290
Study 34023255 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal OCT findings (not specified)
Number of subjects: 1290
Study 34023265 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control intervention
Number of subjects: 0
Study 34023265 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 34023270 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 538
Study 34023270 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 538
Study 34023270 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with pre-PCI FFR ≤0.8 and post-PCI FFR >0.8
Number of subjects: 538
Study 34023270 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 538
Study 34023350 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week course of sofosbuvir-velpatasvir (short arm, n=93)
Number of subjects: 188
Study 34023350 — intervention group
Group type: COMPARATOR
Intervention: 12-week course of sofosbuvir-velpatasvir (standard arm, n=95)
Number of subjects: 188
Study 34023350 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week course of sofosbuvir-velpatasvir (modified ITT analysis)
Number of subjects: 188
Study 34023350 — intervention group
Group type: COMPARATOR
Intervention: 12-week course of sofosbuvir-velpatasvir (modified ITT analysis)
Number of subjects: 188
Study 34023558 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 141
Study 34023735 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 7698
Study 34023735 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anemia
Number of subjects: 7698
Study 34023735 — intervention group
Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 7698
Study 34024024 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset ATTRv Val30Met amyloidosis
Number of subjects: 1389
Study 34024024 — intervention group
Group type: COMPARATOR
Intervention: Early-onset ATTRv Val30Met amyloidosis
Number of subjects: 1389
Study 34024025 — intervention group
Group type: EXPERIMENTAL
Intervention: Gocovri
Number of subjects: 196
Study 34024025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 34024120 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34024501 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical nutrition support during ICU stay
Number of subjects: 1250
Study 34024501 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection from ICU day 1-4 and prospective observation from day 5-90
Number of subjects: 1250
Study 34024522 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull energy drink (25 cl)
Number of subjects: 20
Study 34024757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined coronary CT angiography (CTA) and myocardial CT perfusion imaging (CTP)
Number of subjects: 381
Study 34024757 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA) and single photon emission tomography (SPECT)
Number of subjects: 381
Study 34024757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CTA-CTP
Number of subjects: 381
Study 34024757 — intervention group
Group type: COMPARATOR
Intervention: Combined ICA-SPECT
Number of subjects: 381
Study 34025448 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG) features including five pulse interval variability, four amplitude features, and a novel autocorrelation-based morphology feature.
Number of subjects: 359
Study 34025640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial and systemic immunoadjuvants with low-dose reirradiation
Number of subjects: 30
Study 34025651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study 34025681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lenalidomide plus dexamethasone
Number of subjects: 41
Study 34025756 — intervention group
Group type: EXPERIMENTAL
Intervention: First-step screening with brief tests covering PICS domains
Number of subjects: 0
Study 34025756 — intervention group
Group type: EXPERIMENTAL
Intervention: Second extended assessment if indicated
Number of subjects: 0
Study 34026647 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-EGFRvIII cells
Number of subjects: 1
Study 34026778 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) as an adjunct therapy for COVID-19
Number of subjects: 0
Study 34026778 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive transcutaneous vagal nerve stimulation (t-VNS)
Number of subjects: 0
Study 34026778 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological strategies (e.g., tocilizumab, corticosteroids)
Number of subjects: 0
Study 34026784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cell therapy followed by haploidentical hematopoietic stem cell transplantation (haploidentical-HSCT)
Number of subjects: 1
Study 34026784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T cell therapy
Number of subjects: 1
Study 34026784 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 1
Study 34027223 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system intervention combined with an aspirin awareness media campaign
Number of subjects: 267
Study 34027223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 267